Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.
International Chemical Investors Group (ICIG) has acquired the European Advanced Organics business from Valtris Specialty Chemicals. The transaction includes production plants in Tessenderlo, Belgium, and Maastricht, the Netherlands, as well as the benzyl chloride and derivatives portfolio manufactured at those sites.
US-headquartered Avid Bioservices, a biologics-oriented CDMO, will be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. The three companies have signed a corresponding agreement.
US specialty chemicals company Solenis has acquired BASF’s flocculants business for mining applications. With this strategic acquisition, Solenis enhances its portfolio for mining and mineral processing customers. The transaction, for which financial details were not disclosed, was first announced in July.
US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.
LyondellBasell (LYB) has completed its acquisition of APK in Merseburg, Germany. The company will be fully integrated and continue as part of LYB. The deal was first announced in August of this year.
US paints and coatings group PPG has reached a definitive agreement to sell 100% of its architectural coatings business in the US and Canada to investor American Industrial Partners (AIP) for $550 million.
Sanofi has entered into talks with Clayton Dubilier & Rice (CD&R), a US-based investment company, about the potential sale of a 50% controlling stake in the French drugmaker‘s consumer healthcare business, Opella.
Danish drugmaker Lundbeck has announced to acquire US company Longboard Pharmaceuticals in a deal valued at approximately $2.6 billion. Longboard, headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases.
Sudarshan Chemical Industries Limited (SCIL) recently announced that it has entered into a definitive agreement with the Germany-based Heubach Group, on its acquisition in a combination of an asset and share deal. Sudarshan aims to expand its global presence and pigment portfolio across 19 sites to provide customers with a top-tier product range.
OneSource Specialty Pharma, a newly incorporated CDMO, formed from the merger of three CDMO businesses within the Strides Group. The company has a 30-year track record and specializes in biologics, drug-device combinations, and soft gelatin capsules.
Rio Tinto announced that it will acquire Arcadium Lithium in an all-cash transaction for $5.85 per share that values Arcadium’s at approximately $6.7 billion.
Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was announced in March of this year.
Azelis has signed an agreement to acquire 100% of the shares of Hortimex, a specialty chemicals distributor active in the food ingredients and nutraceuticals segments serving the Polish market.
Keen Vision Acquisition Corp. (KVAC) and Medera, a clinical-stage biotechnology company, have entered into a merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company will operate under the name Medera.
Belgium-headquartered biopharmaceutical company UCB is to sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and investor Mubadala, based in Abu Dhabi, for $680 million.
US paints and coatingsmaker PPG has agreed to sell its silicas products business for abou $310 million to Warsaw, Poland-based Qemetica, a manufacturer of soda ash, silicates and other specialty chemicals. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions.
US industrial gases producer Air Products has agreed to acquire Saneg’s hydrogen production assets at the Fergana oil refinery in Uzbekistan for $140 million.
In a move to grow and upgrade its circular and low carbon solutions business, chemical producer LyondellBasell is to acquire full ownership of plastic recycler APK in Merseburg, Germany. Closing of the transaction is subject to customary closing conditions. Financial details of the deal have not been disclosed.
Bora Pharmaceuticals, a Taiwan-headquartered contract development and manufacturing organization (CDMO), has completed the acquisition of Emergent BioSolutions' sterile manufacturing facility in Baltimore-Camden, Maryland, USA. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.
Eli Lilly has completed its acquisition of Morphic, is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. The $3.2 billion deal was initially agreed upon by the companies in July 2024.
Manuchar, a global chemical distributor with headquarters in Antwerp, Belgium, has agreed to acquire a majority stake in Chilean company Proquiel Químicos.
Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.
US-headquartered biotech firm Recursion has announced that it will acquire UK-based pharmatech Exscientia in an all-stock deal. The transaction, which is expected to close in early 2025, would provide the combined entity with approximately $850 million in cash to fund its operations for the next three years. Reuters reported that Recursion will pay $688 million for the acquisition of Exscientia.
French specialty chemicals producer SNF has agreed to acquire PfP Industries and Ace Fluid Solutions, two oil and gas fluids firms based in Texas, USA. The strategic acquisitions, SNP said, expands its offerings for the company’s upstream oil and gas customers. Financial terms of the transactions were not disclosed.
In a move to accelerate its expansion into the $15 billion global waterproofing tape market, US adhesives major H.B. Fuller has acquired HS Butyl, the UK’s largest manufacturer and distributor of butyl tapes for a wide variety of applications within the construction, infrastructure, automotive and renewable energy industries. Financial details of the transaction were not disclosed.
AbbVie has completed its acquisition of Cerevel Therapeutics. According to AbbVie, Cerevel's pipeline is highly complementary to its own existing neuroscience portfolio. The takeover was announced in December 2023.
Global specialty ingredients solution provider Barentz International recently announced the acquisition of Anshul Life Sciences in India, a specialty chemicals distributor that caters to regulated pharmaceuticals, food & nutraceuticals, and personal care markets.
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
Honeywell and Air Products recently announced that Honeywell has agreed to acquire Air Products’ liquefied natural gas (LNG) process technology and equipment business for €1.67 billion ($1.81 billion) in an all-cash transaction. This represents approximately 13x the estimated 2024 EBITDA.
Syensqo has completed the acquisition of a controlling stake in Azerys, a specialist in rosemary extraction with assets in El Jadida, Morocco.
In a move to enter the activated carbon market for micropollutants removal, Finnish chemicals company Kemira has agreed to purchase Norit’s UK reactivation business from Purton Carbons. The deal is expected to close in the third quarter of2024. Financial details of the deal were not disclosed.
South Korea-headquartered contract development and manufacturing organization (CDMO) SK Bioscience plans to acquire a 60% stake in IDT Biologika, a German CDMO specialized in vaccines, gene and immune therapy and oncolytic viruses, from Klocke Group. Klocke will retain a 40% stake in IDT Biologika and thus remains the company's second-largest shareholder.
AbbVie has acquired Celsius Therapeutics, a privately held biotechnology company developing new therapies inflammatory diseases, for $250 million in cash. The transaction is subject to certain customary adjustments.
In a move to enhance its chemistry, manufacturing and controls (CMC) capabilities, UK-based process research and development contract research organization (CRO) CatSci has acquired chromatography provider Reach Separations. Financial details of the transaction were not disclosed.
